Please assess the completion status of the following clinical trial:

Trial Title: Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
* 15 years of age or older~* Patients with metastatic sarcoma who have had no more than one prior systemic treatment for metastatic disease~* Patients with recurrent sarcoma at relapse~* Patients with confirmed histological diagnosis of sarcoma or suspected diagnosis of sarcoma. Some specific subtypes of sarcoma are NOT eligible (Gastrointestinal Stromal Tumor (GIST), carcinosarcoma, sarcomatoid mesothelioma, and metastatic phyllodes tumor)~* If initial suspected diagnosis of sarcoma, must have sarcoma diagnosis confirmed prior to proceeding with PDX drug sensitivity testing~* Must have measureable disease for computed tomography (CT) scan or magnetic resonance imaging (MRI) evaluation following biopsy or surgery to obtain tissue for PDX development.~* No plan for concurrent chemoradiation, for target lesions that will be used for drug treatment correlation with PDX~* Fresh tumor tissue available for PDX development~* Eastern Cooperative Oncology Group performance status of 0-1~* Life expectancy exceeds 6 months~* Plan to receive systemic therapy~* Informed consent

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PDX drug sensitivity testing (Type: OTHER): Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).